Pathologic Findings and Management of Renal Mass in Horseshoe Kidneys.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
08 2022
Historique:
received: 31 01 2022
revised: 28 02 2022
accepted: 06 03 2022
pubmed: 12 4 2022
medline: 3 8 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

To evaluate the management, surgical outcomes, and pathological findings in patients with tumor in a horseshoe-kidney (HK). HK patients present unique challenges due to aberrant vascular anatomy and risk of renal insufficiency. We hypothesized that many tumors in this setting may be indolent or benign. Patients managed for renal mass in HK at our center (1999-2021) were reviewed. Baseline characteristics, surgical approach, complications, functional outcomes, pathology, and survival were analyzed. Forty-three procedures were performed in 42 patients with HK including 24 nephron-sparing surgeries (NSS) and 19 radical nephrectomies (RN: splitting the isthmus and saving the contralateral moiety). NSS included 22 partial nephrectomy (PN) and 2 thermal ablations. Median tumor size was 4.3 cm. Eighteen cases (42%) were minimally-invasive, 17 open-midline, and 8 other open approaches. Ninety-day Clavien III-V complication rate was 12% with no mortalities. For PN, median warm/cold ischemia times were 26/31 minutes, respectively. On pathology, only 27 tumors (63%) were renal-cell-carcinoma (RCC), and 22 tumors (51%) were either benign (n = 10) or low grade, confined RCC (n = 12). Preoperative/new baseline/long-term eGFR were 82/83/78 mL/min/1.73 m Management of renal masses in HK is challenging and requires versatility with multiple surgical approaches. Preservation of renal function was accomplished in most patients, with a functional advantage observed for NSS. RCC was less common than expected while benign and non-aggressive tumors were prevalent, suggesting consideration for preoperative renal-mass-biopsy when feasible.

Identifiants

pubmed: 35405205
pii: S0090-4295(22)00263-1
doi: 10.1016/j.urology.2022.03.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

170-176

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Yosuke Yasuda (Y)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

J J Zhang (JJ)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Worapat Attawettayanon (W)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Nityam Rathi (N)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Gustavo Roversi (G)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Ao Zhang (A)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Diego Aguilar Palacios (DA)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Georges-Pascal Haber (GP)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Venkatesh Krishnamurthi (V)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Mohamed Eltemamy (M)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Robert Abouassaly (R)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Charles E Martin (CE)

Interventional Radiology, Cleveland Clinic, Cleveland, OH.

Christopher Weight (C)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Steven C Campbell (SC)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: campbes3@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH